Navigation Links
NanoLogix Inc. Files Multiple International Patent Applications for BioNanoChannel(TM) and Hydrogen Bioreactor Technology
Date:11/28/2007

HUBBARD, Ohio, Nov. 28 /PRNewswire-FirstCall/ -- NanoLogix, Inc. (OTC: NNLX - News) a nano-biotechnology company announces that the company has submitted international patent applications for BioNanoChannel(TM) and Hydrogen Bioreactor technology protection for China, India, Brazil, and the EU (European Union). These filings are necessary prior to the anticipated global roll-out of the company's BioNanoChannel(TM) rapid bacteria/microorganism detection technology and also contribute to the protection of NanoLogix's ongoing Hydrogen Bioreactor development.

Chris Novak, NanoLogix Director of IP stated: "The strength and improved focus of the new foreign cases arose from significant improvements to the originally filed provisional patent applications. We at NanoLogix are very excited about the potential for enhancing the patent protection for these new technologies."

According to Bret Barnhizer, NanoLogix President and CEO, "This is a step forward for the company in its plans for technological and business development and sets the stage for one of our corporate goals of pursuing licensing opportunities for use of our products internationally. These applications aid us by ensuring that NanoLogix strengthens their control over the intellectual property rights to the technology."

About NanoLogix, Inc.

NanoLogix is a leading innovator in the research, development, and commercialization of nano-biotechnologies, applications and processes. The Company has 31 granted Patents and 36 Patents Pending for bioreactor-based Hydrogen Production, revolutionary rapid medical testing technologies, potential treatments for sepsis and cancer (via apoptosis), and bioremediation. Information on NanoLogix is available at http://www.nanologixinc.com.

This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

Contact:

Investor Relations

Bret Barnhizer, CEO

Telephone: 330-534-0800

E-mail: Bret@nanologixinc.com


'/>"/>
SOURCE NanoLogix, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Alvarado Hospital Files Countersuit Against Blue Shield
2. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
3. Pharsight Files Application for Nasdaq Capital Market Listing
4. Gentiva(R) Health Services Files Universal Shelf Registration Statement
5. Paramount Acquisition Corp. Files Amendment to Preliminary Proxy Statement for Proposed Acquisition of Chem Rx
6. CIGNA Behavioral Health Offers Members Online Provider Profiles
7. American Media Operations, Inc. Files Form 10-Q For First Quarter 2007
8. RxElite Files Registration Statement with Securities and Exchange Commission
9. Dynamic Files Articles of Merger; Notifies Nasdaq of Merger with GeoPharma
10. Mach One Corporation Files its Form SB-2 with the SEC
11. CryoCath files patent infringement lawsuit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... California (PRWEB) , ... May ... ... a nationwide provider of communication enabled solutions and managed services today announced ... software for the enterprise contact center market. , Altura, one of Avaya’s ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... Center at Sentara Northern Virginia Medical Center located in Woodbridge, VA. The ... surgical services into a single site. , The new 2 story building houses ...
(Date:5/24/2016)... ... May 24, 2016 , ... New Brunswick, New Jersey: This ... healthcare needs reach their fullest potential. To commemorate the anniversary, the hospital has themed ... Walk n’ Roll for Children’s Specialized Hospital Foundation on Saturday, May 21, at Johnson ...
(Date:5/24/2016)... , ... May 24, 2016 , ... Regenerative Medicine is ... in adult stem cell therapy technology, protocols and patient results as have been achieved ... to become a more accessible standard of care for patients worldwide. , As the ...
(Date:5/24/2016)... CA (PRWEB) , ... May 24, 2016 , ... Loma ... house the new adult hospital and expanded Children’s Hospital. Over 3,000 people looked on ... , Check out the event photo slidehsow. , During the program, Richard ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... India , May 25, 2016 ... Review, H1 2016"market research report that provides an ... with comparative analysis at various stages, therapeutics assessment ... of administration (RoA) and molecule type, along with ... It also reviews key players involved in the ...
(Date:5/24/2016)... -- Diana Russell suffers from a form of rheumatoid arthritis ... This disease has put her in a wheelchair, and ... to leave her home.  Because of the size and ... wheelchair.  So if there is a family function, the ... to wait for the bus. Photo - ...
(Date:5/24/2016)... The innovator of COMBO ... s first dual therapy stent, introduces catheters for ... OrbusNeich, a global company specializing in the provision of ... products to treat peripheral artery disease. The JADE™ and ... for lower limb and arteriovenous (AV) fistula intervention. ...
Breaking Medicine Technology: